Key features and details
- Mouse monoclonal [34bE12] to HMW Cytokeratin
- Suitable for: IHC-P, IHC-Fr
- Reacts with: Human
- Isotype: IgG1
製品名Anti-HMW Cytokeratin antibody [34bE12]
製品の詳細Mouse monoclonal [34bE12] to HMW Cytokeratin
アプリケーション適用あり: IHC-P, IHC-Frmore details
Solubilized keratin extract from human stratum corneum.
保存方法Shipped at 4°C. Store at +4°C short term (1-2 weeks). Store at -20°C or -80°C. Avoid freeze / thaw cycle.
バッファーPreservative: 0.05% Sodium azide
Constituents: Tissue culture supernatant, 1% BSA
Concentration information loading...
精製度Tissue culture supernatant
Our Abpromise guarantee covers the use of ab776 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Staining Protocol: We suggest an incubation period of 30-60 minutes at room temperature.
However, depending upon the fixation conditions and the staining system employed, optimal incubation conditions and antibody dilutions should be determined by the user.
Enzymatic antigen retrieval of paraffin embedded tissues is recommended prior to immunostaining.
関連性Cytokeratins are intermediate filament keratins found in the intracytoplasmic cytoskeleton of epithelial tissue. There are two types of Cytokeratins: the low weight, acidic type I cytokeratins and the high weight, basic or neutral type II. Cytokeratins are usually found in pairs comprising a type I Cytokeratin and a type II cytokeratin. The high molecular weight cytokeratins, which are the basic or neutral cytokeratins, comprise subtypes CK1 (67), CK2 (65.5), CK3 (64), CK4 (59), CK5 (58), CK6 (56), CK7 (54), CK8 (52.5) and CK9. The low molecular weight cytokeratins, which are the acidic cytokeratins, comprise subtypes CK10 (56.5), CK12 (56), CK13 (53), CK14 (50), CK16( 48), CK17 (46), CK18 (45), CK19(48) and CK20(46).
- CK13 antibody
- CK14 antibody
- CK15 antibody
ab776 は 1 報の論文で使用されています。
- Hagman Z et al. miR-205 negatively regulates the androgen receptor and is associated with adverse outcome of prostate cancer patients. Br J Cancer 108:1668-76 (2013). IHC ; Human . PubMed: 23571738